|Articles|May 26, 2017

Contagion&reg Interviews Pat Smith to Mark Lyme Disease Awareness Month

Author(s)PRESS RELEASE

In recognition of Lyme disease awareness month, Contagion® interviewed Pat Smith, president of Lyme Disease Association, Inc, to better understand current issues surrounding the diagnosis and treatment of Lyme disease.

CRANBURY, N.J.--(BUSINESS WIRE)--In recognition of Lyme disease awareness month, Contagion®, the nation’s leading digital and print publication that provides practitioners and specialists working in the infectious disease field with disease-specific information, interviewed Pat Smith, president of Lyme Disease Association, Inc, to better understand current issues surrounding the diagnosis and treatment of Lyme disease.

Contagion® Interviews Pat Smith to Mark Lyme Disease Awareness Month

Tweet this

Recent studies have shown that tick-borne disease (TBD)-related cases have tripled since 1992; however, it has become more difficult to recognize the disease. During the interview, Pat Smith said, “Even 43 years into Lyme disease, there’s still a lot of problems with recognizing Lyme disease.”

Smith continued by explaining the accuracy of the Lyme disease test, “The testing is probably about 50 percent accurate (the test that’s being used now, the two-step test).”

While discussing the diagnosis process, Smith stated, “Physicians aren’t always diagnosing Lyme, and so, patients can’t get diagnosed easily or in a timely manner.” She added, “If it takes a long time for diagnosis, then it takes a longer time for a patient to get treatment. In the meantime, the bacteria are in their body replicating. Therefore, this is very problematic.” Smith addresses the current issues concerning the diagnosis and treatment of Lyme disease even further in a commentary published on the Contagion® website: http://www.contagionlive.com/news/is-the-medical-community-behind-the-times-when-it-comes-to-treating-lyme.

To view the interview featuring Pat Smith, please visit contagionlive.com/link/4

About Contagion®

Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets and Outbreak Monitor, we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment and prevention of infectious diseases. Our mission is to assure that the health care community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.

Contacts

Contagion® Media:

Theresa Burek/609-716-7777 ext. 811

tburek@mjhassoc.com

or

Surabhi Verma/609-716-7777 ext. 851

sverma@mjhassoc.com


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.